Quick Overview of Boston Scientific

By Susan Ramirez • Monday, December 11 12:08 • Permanent Link

More and more people are talking about Boston Scientific over the last few weeks. Is it worth buying the Medical Instruments & Supplies stock at a price of $55.24? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Boston Scientific has moved 16.6% over the last year, and the S&P 500 logged a change of 15.4%
BSX has an average analyst rating of buy and is -9.03% away from its mean target price of $60.72 per share
Its trailing earnings per share (EPS) is $0.82
Boston Scientific has a trailing 12 month Price to Earnings (P/E) ratio of 67.4 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $2.24 and its forward P/E ratio is 24.7
The company has a Price to Book (P/B) ratio of 4.28 in contrast to the S&P 500's average ratio of 2.95
Boston Scientific is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
BSX has reported YOY quarterly earnings growth of 183.3% and gross profit margins of 0.7%
The company has a free cash flow of $1.87 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.